Ranbaxy Expected To Move Mohali ANDA's To U.S. Ohm Labs Unit
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories, beset by rejection of its third and newest production plant, at Mohali, is likely to consider shifting U.S.-bound work to its U.S. unit, Ohm Labs, according to analysts.